ScholarLens Back to search
2019•Obstetric Anesthesia DigestRequires access

A Systematic Review of the Cost-effectiveness of Uterotonic Agents for the Prevention of Postpartum Hemorrhage

T.A. Lawri, Ewelina Rogozińska, Pauline Sobiesuo, Joshua P. Vogel, Lucy Ternent, T. Oladapo

Open publisher page 0 citations

Abstract

(Int J Gynecol Obstet. 2019;146:56–64) Around 5% of women giving birth worldwide experience postpartum hemorrhage (PPH). PPH is defined as blood loss of ≥500 mL within a day of birth and most often occurs when the uterus does not contract following delivery. All women giving birth should be offered a uterotonic agent in the third stage of labor, according to World Health Organization (WHO) guidelines. Uterotonic agents for PPH prevention include oxytocin, ergometrine, misoprostol, carbetocin, injectable prostaglandins and syntometrine (a combination of ergometrine and oxytocin). WHO recommends oxytocin as a first-choice uterotonic for the prevention of PPH. Previous single-setting studies have assessed single uterotonics for cost-effectiveness. This review aimed to assess the cost-effectiveness of all available options of uterotonic agents for the prevention of PPH.

About this research paper

What this paper is about

(Int J Gynecol Obstet. 2019;146:56–64) Around 5% of women giving birth worldwide experience postpartum hemorrhage (PPH). PPH is defined as blood loss of ≥500 mL within a day of birth and most often occurs when the uterus does not contract following delivery. All women giving birth should be offered a uterotonic agent in the third stage of labor, according to World Health Organization (WHO) guidelines. Uterotonic agents for PPH prevention include oxytocin, ergometrine, misoprostol, carbetocin, injectable prostaglandins and syntometrine (a combination of ergometrine and oxytocin). WHO recommends oxytocin as a first-choice uterotonic for the prevention of PPH. Previous single-setting studies have assessed single uterotonics for cost-effectiveness. This review aimed to assess the cost-effectiveness of all available options of uterotonic agents for the prevention of PPH.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

(Int J Gynecol Obstet. 2019;146:56–64) Around 5% of women giving birth worldwide experience postpartum hemorrhage (PPH). PPH is defined as blood loss of ≥500 mL within a day of birth and most often occurs when the uterus does not contract following delivery. All women giving birth should be offered a uterotonic agent in the third stage of labor, according to World Health Organization (WHO) guidelines. Uterotonic agents for PPH prevention include oxytocin, ergometrine, misoprostol, carbetocin, injectable prostaglandins and syntometrine (a combination of ergometrine and oxytocin). WHO recommends oxytocin as a first-choice uterotonic for the prevention of PPH. Previous single-setting studies have assessed single uterotonics for cost-effectiveness. This review aimed to assess the cost-effectiveness of all available options of uterotonic agents for the prevention of PPH.

Key concepts: Uterotonic, Misoprostol, Medicine, Ergometrine, Oxytocin, Obstetrics, Postpartum haemorrhage, Pregnancy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A Systematic Review of the Cost-effectiveness of Uterotonic Agents for the Prevention of Postpartum Hemorrhage — Research Paper | ScholarLens